Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 11/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 6/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 6/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 5/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470160 | 0.84 | FYN (0.47) | FYNPDE4DDYRK1A | |
| SCHEMBL521339 | 0.82 | FYN (0.41) | FYNPDE4DDYRK1ADYRK2DYRK1B | |
| SCHEMBL521326 | 0.80 | KDM4E (0.45) | FYNDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL519748 | 0.78 | JAK2 (0.56) | — | |
| SCHEMBL3470162 | 0.77 | CDK9 (0.42) | FYNDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL519160 | 0.76 | DYRK3 (0.43) | FYNDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL521425 | 0.76 | FYN (0.50) | FYNDYRK1ADYRK2DYRK1BDYRK3 | |
| SCHEMBL520344 | 0.76 | DYRK1A (0.45) | DYRK1ADYRK2DYRK1BDYRK3CCNA2 | |
| SCHEMBL520662 | 0.75 | INSR (0.44) | FYNDYRK1ADYRK1B | |
| SCHEMBL520240 | 0.75 | KCNH2 (0.48) | FYNDYRK1ADYRK2DYRK1BDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | FYN 195/4885PDE4D 3374/4885DYRK1A 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.